Iris Jung-won Lee, MD, Interim Chief of the Section of Nephrology at Temple University Hospital, provided perspective to Rare Disease Advisor on new data presented at the American Society of Nephrology Kidney Week 2026 that highlighted the benefits and limitations of investigational and FDA-approved therapies for immunoglobulin A nephropathy (IgAN).